Seeing Is Believing
Currently out of the existing stock ratings of Keay Nakae, 202 are a BUY (88.6%), 18 are a HOLD (7.89%), 8 are a SELL (3.51%).
Analyst Keay Nakae, currently employed at CHARDAN CAPITAL, carries an average stock price target met ratio of 43.04% that have a potential upside of 37.16% achieved within 97 days.
Keay Nakae’s has documented 395 price targets and ratings displayed on 38 stocks. The coverage is on the Healthcare sector.
Most recent stock forecast was given on SABS, SAB Biotherapeutics at 19-Sep-2025.
Analyst best performing recommendations are on KMDA (KAMADA).
The best stock recommendation documented was for EVLO (EVELO BIOSCIENCES) at 11/1/2021. The price target of $240 was fulfilled within 4 days with a profit of $50.6 (26.72%) receiving and performance score of 66.79.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Days to Hit Target
Performance score
Buy
$5
$0.62 (14.16%)
$5
1 months 29 days ago
(10-Aug-2025)
4/13 (30.77%)
$1.65 (49.25%)
136
Buy
$5
$0.62 (14.16%)
$5
8 months 19 days ago
(20-Jan-2025)
0/17 (0%)
$1.79 (55.76%)
Buy
$5
$0.62 (14.16%)
$4
1 years 2 months 8 days ago
(01-Aug-2024)
2/6 (33.33%)
$1.26 (33.69%)
256
Buy
$5
$0.62 (14.16%)
3 years 8 months 8 days ago
(01-Feb-2022)
0/1 (0%)
$2.11 (73.01%)
Buy
$7
4 years 3 months 12 days ago
(27-Jun-2021)
0/4 (0%)
$3.7 (112.12%)
Which stock is Keay Nakae is most bullish on?
Which stock is Keay Nakae is most reserved on?
What Year was the first public recommendation made by Keay Nakae?